Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520698 | 0.91 | NR1H4 (0.40) | CASP1NR1H4 | |
| SCHEMBL4527486 | 0.90 | NR1H4 (0.40) | ALDH1A1KDM4ENR1H4MAPT | |
| SCHEMBL4526606 | 0.89 | NR1H4 (0.38) | ALDH1A1KDM4ENR1H4 | |
| SCHEMBL4525379 | 0.88 | NR1H4 (0.46) | ALDH1A1KDM4ENR1H4MEN1ALOX15 | |
| SCHEMBL4523812 | 0.86 | HRH4 (0.42) | NR1H4GAATLR9TLR8TLR7 | |
| SCHEMBL4523445 | 0.86 | NR1H4 (0.41) | NR1H4GAA | |
| SCHEMBL4528374 | 0.84 | NR1H4 (0.38) | NR1H4TLR9TLR8TLR7 | |
| SCHEMBL4528016 | 0.84 | L3MBTL3 (0.40) | ALDH1A1NR1H4 | |
| SCHEMBL4531385 | 0.84 | CACNA2D1 (0.44) | NR1H4 | |
| SCHEMBL4525870 | 0.83 | NR1H4 (0.43) | ALDH1A1NR1H4MAPTALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | ALDH1A1 622/4885KDM4E 3410/4885HPGD 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.